Table 1.

FDA-approved SGLT2is commercially available in the United States as of January 2021

Indication	Canagliflozin	Dapagliflozin	Empagliflozin	Ertugliflozin
Antiglycemic	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Cardiovascular disease	Reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease	Reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple risk factors	Reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Heart failure	Partial (see below)	Reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (NYHA classification II–IV)
Renal disease	Reduce the risk of ESKD, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ˃300 mg/d	Breakthrough therapy designation in the United States for patients with CKD with and without type 2 diabetes (indication pending)

FDA, Food and Drug Administration; SGLT2is, sodium-glucose cotransporter 2 inhibitors; NYHA, New York Heart Association.